nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—SIK1—dilated cardiomyopathy	0.474	0.697	CbGaD
Dabrafenib—RAF1—dilated cardiomyopathy	0.206	0.303	CbGaD
Dabrafenib—SLC22A8—Furosemide—dilated cardiomyopathy	0.0598	0.3	CbGbCtD
Dabrafenib—SLC22A6—Furosemide—dilated cardiomyopathy	0.0417	0.209	CbGbCtD
Dabrafenib—CYP2C8—Spironolactone—dilated cardiomyopathy	0.0401	0.201	CbGbCtD
Dabrafenib—ABCB1—Lisinopril—dilated cardiomyopathy	0.0309	0.155	CbGbCtD
Dabrafenib—ABCB1—Spironolactone—dilated cardiomyopathy	0.0272	0.136	CbGbCtD
Dabrafenib—Gastric haemorrhage—Spironolactone—dilated cardiomyopathy	0.0104	0.196	CcSEcCtD
Dabrafenib—Rash erythematous—Spironolactone—dilated cardiomyopathy	0.0017	0.032	CcSEcCtD
Dabrafenib—Hyperkalaemia—Spironolactone—dilated cardiomyopathy	0.00128	0.0241	CcSEcCtD
Dabrafenib—LIMK1—heart—dilated cardiomyopathy	0.00116	0.158	CbGeAlD
Dabrafenib—Hypomagnesaemia—Furosemide—dilated cardiomyopathy	0.00112	0.021	CcSEcCtD
Dabrafenib—Nephritis interstitial—Furosemide—dilated cardiomyopathy	0.00105	0.0198	CcSEcCtD
Dabrafenib—Renal failure acute—Spironolactone—dilated cardiomyopathy	0.00103	0.0193	CcSEcCtD
Dabrafenib—Azotaemia—Lisinopril—dilated cardiomyopathy	0.000999	0.0188	CcSEcCtD
Dabrafenib—Tubulointerstitial nephritis—Furosemide—dilated cardiomyopathy	0.000927	0.0174	CcSEcCtD
Dabrafenib—SIK1—cardiac ventricle—dilated cardiomyopathy	0.000913	0.124	CbGeAlD
Dabrafenib—SIK1—myocardium—dilated cardiomyopathy	0.000858	0.117	CbGeAlD
Dabrafenib—Hypocalcaemia—Furosemide—dilated cardiomyopathy	0.000775	0.0146	CcSEcCtD
Dabrafenib—RAF1—cardiac ventricle—dilated cardiomyopathy	0.000726	0.0989	CbGeAlD
Dabrafenib—Renal failure—Spironolactone—dilated cardiomyopathy	0.000717	0.0135	CcSEcCtD
Dabrafenib—BRAF—heart—dilated cardiomyopathy	0.000716	0.0974	CbGeAlD
Dabrafenib—RAF1—myocardium—dilated cardiomyopathy	0.000683	0.093	CbGeAlD
Dabrafenib—SIK1—heart—dilated cardiomyopathy	0.000599	0.0816	CbGeAlD
Dabrafenib—Oropharyngeal pain—Lisinopril—dilated cardiomyopathy	0.000585	0.011	CcSEcCtD
Dabrafenib—Alopecia—Spironolactone—dilated cardiomyopathy	0.000579	0.0109	CcSEcCtD
Dabrafenib—Creatinine increased—Lisinopril—dilated cardiomyopathy	0.000559	0.0105	CcSEcCtD
Dabrafenib—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.000548	0.0103	CcSEcCtD
Dabrafenib—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.000539	0.0101	CcSEcCtD
Dabrafenib—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.000523	0.00984	CcSEcCtD
Dabrafenib—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.000517	0.00973	CcSEcCtD
Dabrafenib—Influenza like illness—Lisinopril—dilated cardiomyopathy	0.000517	0.00973	CcSEcCtD
Dabrafenib—SIK1—cardiac atrium—dilated cardiomyopathy	0.000512	0.0698	CbGeAlD
Dabrafenib—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00051	0.0096	CcSEcCtD
Dabrafenib—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.000483	0.00908	CcSEcCtD
Dabrafenib—Dehydration—Furosemide—dilated cardiomyopathy	0.000479	0.00901	CcSEcCtD
Dabrafenib—RAF1—heart—dilated cardiomyopathy	0.000477	0.0649	CbGeAlD
Dabrafenib—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.000469	0.00882	CcSEcCtD
Dabrafenib—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.000456	0.00857	CcSEcCtD
Dabrafenib—Pancreatitis—Furosemide—dilated cardiomyopathy	0.000436	0.00821	CcSEcCtD
Dabrafenib—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.000419	0.00788	CcSEcCtD
Dabrafenib—RAF1—cardiac atrium—dilated cardiomyopathy	0.000408	0.0555	CbGeAlD
Dabrafenib—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000402	0.00756	CcSEcCtD
Dabrafenib—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.000402	0.00756	CcSEcCtD
Dabrafenib—Renal failure—Furosemide—dilated cardiomyopathy	0.00039	0.00734	CcSEcCtD
Dabrafenib—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.000388	0.0073	CcSEcCtD
Dabrafenib—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.000386	0.00727	CcSEcCtD
Dabrafenib—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000368	0.00692	CcSEcCtD
Dabrafenib—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.000362	0.00681	CcSEcCtD
Dabrafenib—Dehydration—Lisinopril—dilated cardiomyopathy	0.000359	0.00676	CcSEcCtD
Dabrafenib—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.000352	0.00662	CcSEcCtD
Dabrafenib—Urethral disorder—Furosemide—dilated cardiomyopathy	0.000349	0.00657	CcSEcCtD
Dabrafenib—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.000346	0.0065	CcSEcCtD
Dabrafenib—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000343	0.00645	CcSEcCtD
Dabrafenib—Eye disorder—Furosemide—dilated cardiomyopathy	0.000333	0.00627	CcSEcCtD
Dabrafenib—Pruritus—Spironolactone—dilated cardiomyopathy	0.000329	0.00619	CcSEcCtD
Dabrafenib—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.000327	0.00616	CcSEcCtD
Dabrafenib—Angiopathy—Furosemide—dilated cardiomyopathy	0.000323	0.00608	CcSEcCtD
Dabrafenib—Immune system disorder—Furosemide—dilated cardiomyopathy	0.000322	0.00606	CcSEcCtD
Dabrafenib—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000318	0.00599	CcSEcCtD
Dabrafenib—Arrhythmia—Furosemide—dilated cardiomyopathy	0.000318	0.00599	CcSEcCtD
Dabrafenib—Neutropenia—Lisinopril—dilated cardiomyopathy	0.000312	0.00588	CcSEcCtD
Dabrafenib—Malnutrition—Furosemide—dilated cardiomyopathy	0.00031	0.00584	CcSEcCtD
Dabrafenib—Erythema—Furosemide—dilated cardiomyopathy	0.00031	0.00584	CcSEcCtD
Dabrafenib—Dizziness—Spironolactone—dilated cardiomyopathy	0.000308	0.00579	CcSEcCtD
Dabrafenib—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.000301	0.00567	CcSEcCtD
Dabrafenib—Muscle spasms—Furosemide—dilated cardiomyopathy	0.000298	0.00561	CcSEcCtD
Dabrafenib—Vomiting—Spironolactone—dilated cardiomyopathy	0.000296	0.00557	CcSEcCtD
Dabrafenib—Rash—Spironolactone—dilated cardiomyopathy	0.000293	0.00552	CcSEcCtD
Dabrafenib—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000293	0.00552	CcSEcCtD
Dabrafenib—Renal failure—Lisinopril—dilated cardiomyopathy	0.000293	0.00551	CcSEcCtD
Dabrafenib—Vision blurred—Furosemide—dilated cardiomyopathy	0.000292	0.0055	CcSEcCtD
Dabrafenib—Headache—Spironolactone—dilated cardiomyopathy	0.000291	0.00549	CcSEcCtD
Dabrafenib—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.000289	0.00545	CcSEcCtD
Dabrafenib—Anaemia—Furosemide—dilated cardiomyopathy	0.000287	0.00539	CcSEcCtD
Dabrafenib—Haematuria—Lisinopril—dilated cardiomyopathy	0.000284	0.00534	CcSEcCtD
Dabrafenib—Epistaxis—Lisinopril—dilated cardiomyopathy	0.000281	0.00529	CcSEcCtD
Dabrafenib—Leukopenia—Furosemide—dilated cardiomyopathy	0.000278	0.00522	CcSEcCtD
Dabrafenib—Nausea—Spironolactone—dilated cardiomyopathy	0.000276	0.0052	CcSEcCtD
Dabrafenib—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000264	0.00497	CcSEcCtD
Dabrafenib—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.000263	0.00496	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.000262	0.00494	CcSEcCtD
Dabrafenib—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.000262	0.00493	CcSEcCtD
Dabrafenib—Dry mouth—Furosemide—dilated cardiomyopathy	0.000258	0.00486	CcSEcCtD
Dabrafenib—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000248	0.00467	CcSEcCtD
Dabrafenib—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000248	0.00466	CcSEcCtD
Dabrafenib—Skin disorder—Furosemide—dilated cardiomyopathy	0.000246	0.00463	CcSEcCtD
Dabrafenib—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000245	0.00461	CcSEcCtD
Dabrafenib—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000243	0.00456	CcSEcCtD
Dabrafenib—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000241	0.00453	CcSEcCtD
Dabrafenib—Chills—Lisinopril—dilated cardiomyopathy	0.00024	0.00451	CcSEcCtD
Dabrafenib—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.000239	0.00449	CcSEcCtD
Dabrafenib—Hypotension—Furosemide—dilated cardiomyopathy	0.000237	0.00445	CcSEcCtD
Dabrafenib—Alopecia—Lisinopril—dilated cardiomyopathy	0.000236	0.00445	CcSEcCtD
Dabrafenib—Mental disorder—Lisinopril—dilated cardiomyopathy	0.000234	0.00441	CcSEcCtD
Dabrafenib—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000233	0.00438	CcSEcCtD
Dabrafenib—Erythema—Lisinopril—dilated cardiomyopathy	0.000233	0.00438	CcSEcCtD
Dabrafenib—Back pain—Lisinopril—dilated cardiomyopathy	0.000225	0.00424	CcSEcCtD
Dabrafenib—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000224	0.00421	CcSEcCtD
Dabrafenib—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00022	0.00414	CcSEcCtD
Dabrafenib—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000219	0.00413	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000219	0.00411	CcSEcCtD
Dabrafenib—Fatigue—Furosemide—dilated cardiomyopathy	0.000218	0.00411	CcSEcCtD
Dabrafenib—Constipation—Furosemide—dilated cardiomyopathy	0.000216	0.00407	CcSEcCtD
Dabrafenib—Anaemia—Lisinopril—dilated cardiomyopathy	0.000215	0.00405	CcSEcCtD
Dabrafenib—Leukopenia—Lisinopril—dilated cardiomyopathy	0.000208	0.00392	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000207	0.0039	CcSEcCtD
Dabrafenib—Cough—Lisinopril—dilated cardiomyopathy	0.000203	0.00382	CcSEcCtD
Dabrafenib—Body temperature increased—Furosemide—dilated cardiomyopathy	0.0002	0.00377	CcSEcCtD
Dabrafenib—Abdominal pain—Furosemide—dilated cardiomyopathy	0.0002	0.00377	CcSEcCtD
Dabrafenib—Myalgia—Lisinopril—dilated cardiomyopathy	0.000198	0.00373	CcSEcCtD
Dabrafenib—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000198	0.00373	CcSEcCtD
Dabrafenib—ABCG2—heart—dilated cardiomyopathy	0.000197	0.0269	CbGeAlD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000197	0.0037	CcSEcCtD
Dabrafenib—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000194	0.00365	CcSEcCtD
Dabrafenib—Oedema—Lisinopril—dilated cardiomyopathy	0.00019	0.00357	CcSEcCtD
Dabrafenib—Infection—Lisinopril—dilated cardiomyopathy	0.000189	0.00355	CcSEcCtD
Dabrafenib—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000187	0.00351	CcSEcCtD
Dabrafenib—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000186	0.0035	CcSEcCtD
Dabrafenib—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000184	0.00347	CcSEcCtD
Dabrafenib—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000184	0.00346	CcSEcCtD
Dabrafenib—Asthenia—Furosemide—dilated cardiomyopathy	0.000182	0.00342	CcSEcCtD
Dabrafenib—Pruritus—Furosemide—dilated cardiomyopathy	0.000179	0.00337	CcSEcCtD
Dabrafenib—Hypotension—Lisinopril—dilated cardiomyopathy	0.000177	0.00334	CcSEcCtD
Dabrafenib—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000173	0.00326	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000173	0.00326	CcSEcCtD
Dabrafenib—Insomnia—Lisinopril—dilated cardiomyopathy	0.000172	0.00323	CcSEcCtD
Dabrafenib—Dizziness—Furosemide—dilated cardiomyopathy	0.000167	0.00315	CcSEcCtD
Dabrafenib—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000165	0.00311	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000164	0.00309	CcSEcCtD
Dabrafenib—Fatigue—Lisinopril—dilated cardiomyopathy	0.000164	0.00308	CcSEcCtD
Dabrafenib—Constipation—Lisinopril—dilated cardiomyopathy	0.000162	0.00306	CcSEcCtD
Dabrafenib—Vomiting—Furosemide—dilated cardiomyopathy	0.000161	0.00303	CcSEcCtD
Dabrafenib—Rash—Furosemide—dilated cardiomyopathy	0.00016	0.003	CcSEcCtD
Dabrafenib—Dermatitis—Furosemide—dilated cardiomyopathy	0.000159	0.003	CcSEcCtD
Dabrafenib—Headache—Furosemide—dilated cardiomyopathy	0.000159	0.00298	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000155	0.00292	CcSEcCtD
Dabrafenib—Nausea—Furosemide—dilated cardiomyopathy	0.00015	0.00283	CcSEcCtD
Dabrafenib—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00015	0.00283	CcSEcCtD
Dabrafenib—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00015	0.00283	CcSEcCtD
Dabrafenib—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00014	0.00263	CcSEcCtD
Dabrafenib—Asthenia—Lisinopril—dilated cardiomyopathy	0.000136	0.00256	CcSEcCtD
Dabrafenib—Pruritus—Lisinopril—dilated cardiomyopathy	0.000134	0.00253	CcSEcCtD
Dabrafenib—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00013	0.00245	CcSEcCtD
Dabrafenib—Dizziness—Lisinopril—dilated cardiomyopathy	0.000126	0.00236	CcSEcCtD
Dabrafenib—Vomiting—Lisinopril—dilated cardiomyopathy	0.000121	0.00227	CcSEcCtD
Dabrafenib—Rash—Lisinopril—dilated cardiomyopathy	0.00012	0.00225	CcSEcCtD
Dabrafenib—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00012	0.00225	CcSEcCtD
Dabrafenib—Headache—Lisinopril—dilated cardiomyopathy	0.000119	0.00224	CcSEcCtD
Dabrafenib—Nausea—Lisinopril—dilated cardiomyopathy	0.000113	0.00212	CcSEcCtD
Dabrafenib—ABCB1—heart—dilated cardiomyopathy	9.73e-05	0.0132	CbGeAlD
Dabrafenib—RAF1—PDGFR-beta signaling pathway—RAC1—dilated cardiomyopathy	6.93e-05	0.00116	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—RPS6KB1—dilated cardiomyopathy	6.85e-05	0.00115	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	6.82e-05	0.00114	CbGpPWpGaD
Dabrafenib—RAF1—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	6.68e-05	0.00112	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—RAC1—dilated cardiomyopathy	6.67e-05	0.00112	CbGpPWpGaD
Dabrafenib—BRAF—PDGFR-beta signaling pathway—RAF1—dilated cardiomyopathy	6.64e-05	0.00111	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	6.64e-05	0.00111	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	6.64e-05	0.00111	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—RAC1—dilated cardiomyopathy	6.63e-05	0.00111	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—ACTN2—dilated cardiomyopathy	6.6e-05	0.00111	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	6.59e-05	0.0011	CbGpPWpGaD
Dabrafenib—RAF1—Ceramide signaling pathway—TNF—dilated cardiomyopathy	6.45e-05	0.00108	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—PSEN2—dilated cardiomyopathy	6.43e-05	0.00108	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	6.41e-05	0.00107	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	6.41e-05	0.00107	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—AGTR1—dilated cardiomyopathy	6.41e-05	0.00107	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways in Glioblastoma—EGFR—dilated cardiomyopathy	6.38e-05	0.00107	CbGpPWpGaD
Dabrafenib—RAF1—Insulin Signaling—RPS6KB1—dilated cardiomyopathy	6.3e-05	0.00106	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—RAC1—dilated cardiomyopathy	6.29e-05	0.00105	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—CD36—dilated cardiomyopathy	6.25e-05	0.00105	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—RPS6KB1—dilated cardiomyopathy	6.23e-05	0.00104	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	6.21e-05	0.00104	CbGpPWpGaD
Dabrafenib—LIMK1—Axon guidance—RAF1—dilated cardiomyopathy	6.2e-05	0.00104	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—RAC1—dilated cardiomyopathy	6.19e-05	0.00104	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	6.17e-05	0.00103	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—ITGB1—dilated cardiomyopathy	6.17e-05	0.00103	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	6.1e-05	0.00102	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ANKRD1—dilated cardiomyopathy	6.07e-05	0.00102	CbGpPWpGaD
Dabrafenib—BRAF—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	6.07e-05	0.00102	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	6.04e-05	0.00101	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	6.04e-05	0.00101	CbGpPWpGaD
Dabrafenib—RAF1—Regulation of Actin Cytoskeleton—RAC1—dilated cardiomyopathy	6.02e-05	0.00101	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	5.96e-05	0.000999	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—RAC1—dilated cardiomyopathy	5.89e-05	0.000988	CbGpPWpGaD
Dabrafenib—RAF1—SHP2 signaling—EGFR—dilated cardiomyopathy	5.82e-05	0.000976	CbGpPWpGaD
Dabrafenib—RAF1—Cardiac Hypertrophic Response—TNF—dilated cardiomyopathy	5.79e-05	0.00097	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—FASLG—dilated cardiomyopathy	5.79e-05	0.00097	CbGpPWpGaD
Dabrafenib—BRAF—Regulation of Actin Cytoskeleton—RAF1—dilated cardiomyopathy	5.77e-05	0.000967	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	5.75e-05	0.000963	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—TAZ—dilated cardiomyopathy	5.71e-05	0.000957	CbGpPWpGaD
Dabrafenib—RAF1—Insulin Signaling—RAC1—dilated cardiomyopathy	5.69e-05	0.000953	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—RAC1—dilated cardiomyopathy	5.63e-05	0.000944	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	5.61e-05	0.000941	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—VCL—dilated cardiomyopathy	5.61e-05	0.00094	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	5.59e-05	0.000937	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	5.59e-05	0.000937	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—FAS—dilated cardiomyopathy	5.58e-05	0.000935	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—RAC1—dilated cardiomyopathy	5.58e-05	0.000935	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—RAC1—dilated cardiomyopathy	5.47e-05	0.000917	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR—RAF1—dilated cardiomyopathy	5.4e-05	0.000905	CbGpPWpGaD
Dabrafenib—BRAF—EGF/EGFR Signaling Pathway—RAF1—dilated cardiomyopathy	5.4e-05	0.000905	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—IL10—dilated cardiomyopathy	5.37e-05	0.0009	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	5.26e-05	0.000882	CbGpPWpGaD
Dabrafenib—RAF1—AGE/RAGE pathway—EGFR—dilated cardiomyopathy	5.25e-05	0.00088	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—RAC1—dilated cardiomyopathy	5.25e-05	0.000879	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—RAC1—dilated cardiomyopathy	5.25e-05	0.000879	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—RAF1—dilated cardiomyopathy	5.24e-05	0.000879	CbGpPWpGaD
Dabrafenib—BRAF—ErbB1 downstream signaling—EGFR—dilated cardiomyopathy	5.24e-05	0.000878	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	5.22e-05	0.000875	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	5.2e-05	0.000871	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—RAC1—dilated cardiomyopathy	5.17e-05	0.000866	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—SDHA—dilated cardiomyopathy	5.16e-05	0.000865	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	5.04e-05	0.000844	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR in disease—RAF1—dilated cardiomyopathy	5.03e-05	0.000843	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling in naïve CD8+ T cells—TNF—dilated cardiomyopathy	5e-05	0.000838	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	4.99e-05	0.000836	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—RAC1—dilated cardiomyopathy	4.96e-05	0.000831	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	4.95e-05	0.000829	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	4.94e-05	0.000827	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	4.81e-05	0.000806	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—RAF1—dilated cardiomyopathy	4.75e-05	0.000796	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	4.66e-05	0.000781	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—PSEN2—dilated cardiomyopathy	4.59e-05	0.000769	CbGpPWpGaD
Dabrafenib—BRAF—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	4.56e-05	0.000764	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—RAF1—dilated cardiomyopathy	4.45e-05	0.000746	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—RAF1—dilated cardiomyopathy	4.42e-05	0.000742	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways in Glioblastoma—EGFR—dilated cardiomyopathy	4.42e-05	0.00074	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	4.39e-05	0.000736	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	4.29e-05	0.000719	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—ITGB1—dilated cardiomyopathy	4.27e-05	0.000716	CbGpPWpGaD
Dabrafenib—LIMK1—Axon guidance—EGFR—dilated cardiomyopathy	4.25e-05	0.000713	CbGpPWpGaD
Dabrafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—TNF—dilated cardiomyopathy	4.12e-05	0.000691	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ANKRD1—dilated cardiomyopathy	4.08e-05	0.000684	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—ITGB1—dilated cardiomyopathy	4.02e-05	0.000674	CbGpPWpGaD
Dabrafenib—BRAF—Regulation of Actin Cytoskeleton—EGFR—dilated cardiomyopathy	3.96e-05	0.000663	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	3.92e-05	0.000656	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—RAF1—dilated cardiomyopathy	3.91e-05	0.000655	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—TAZ—dilated cardiomyopathy	3.84e-05	0.000643	CbGpPWpGaD
Dabrafenib—RAF1—TNF alpha Signaling Pathway—TNF—dilated cardiomyopathy	3.83e-05	0.000643	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ANKRD1—dilated cardiomyopathy	3.78e-05	0.000633	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR—EGFR—dilated cardiomyopathy	3.7e-05	0.00062	CbGpPWpGaD
Dabrafenib—BRAF—EGF/EGFR Signaling Pathway—EGFR—dilated cardiomyopathy	3.7e-05	0.00062	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD36—dilated cardiomyopathy	3.64e-05	0.00061	CbGpPWpGaD
Dabrafenib—RAF1—ErbB1 downstream signaling—EGFR—dilated cardiomyopathy	3.62e-05	0.000607	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—EGFR—dilated cardiomyopathy	3.6e-05	0.000603	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—RAC1—dilated cardiomyopathy	3.57e-05	0.000599	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—TAZ—dilated cardiomyopathy	3.55e-05	0.000595	CbGpPWpGaD
Dabrafenib—BRAF—Neuronal System—RAF1—dilated cardiomyopathy	3.49e-05	0.000586	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—SDHA—dilated cardiomyopathy	3.47e-05	0.000581	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR in disease—EGFR—dilated cardiomyopathy	3.45e-05	0.000578	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—RAC1—dilated cardiomyopathy	3.43e-05	0.000575	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—RAF1—dilated cardiomyopathy	3.43e-05	0.000574	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—TNF—dilated cardiomyopathy	3.42e-05	0.000574	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—EGFR—dilated cardiomyopathy	3.26e-05	0.000546	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NPPA—dilated cardiomyopathy	3.25e-05	0.000545	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—RAC1—dilated cardiomyopathy	3.23e-05	0.000542	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—SDHA—dilated cardiomyopathy	3.21e-05	0.000538	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PSEN2—dilated cardiomyopathy	3.15e-05	0.000528	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	3.15e-05	0.000528	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	3.11e-05	0.000521	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	3.07e-05	0.000514	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—EGFR—dilated cardiomyopathy	3.05e-05	0.000512	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—EGFR—dilated cardiomyopathy	3.03e-05	0.000509	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	3.02e-05	0.000507	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	3.02e-05	0.000507	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—TNF—dilated cardiomyopathy	2.89e-05	0.000484	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—ITGB1—dilated cardiomyopathy	2.87e-05	0.000481	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—EGFR—dilated cardiomyopathy	2.86e-05	0.00048	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—ITGB1—dilated cardiomyopathy	2.82e-05	0.000472	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	2.81e-05	0.000471	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	2.76e-05	0.000463	CbGpPWpGaD
Dabrafenib—RAF1—Regulation of Actin Cytoskeleton—EGFR—dilated cardiomyopathy	2.74e-05	0.000459	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—EGFR—dilated cardiomyopathy	2.74e-05	0.000459	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—EGFR—dilated cardiomyopathy	2.69e-05	0.000452	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—EGFR—dilated cardiomyopathy	2.68e-05	0.000449	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—EGFR—dilated cardiomyopathy	2.57e-05	0.000431	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—EGFR—dilated cardiomyopathy	2.56e-05	0.000429	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—EGFR—dilated cardiomyopathy	2.56e-05	0.000429	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—EGFR—dilated cardiomyopathy	2.55e-05	0.000427	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—EGFR—dilated cardiomyopathy	2.54e-05	0.000425	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—EGFR—dilated cardiomyopathy	2.49e-05	0.000417	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	2.46e-05	0.000413	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—CD36—dilated cardiomyopathy	2.45e-05	0.000411	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—ITGB1—dilated cardiomyopathy	2.44e-05	0.000408	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—CD36—dilated cardiomyopathy	2.4e-05	0.000403	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—EGFR—dilated cardiomyopathy	2.39e-05	0.0004	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—EGFR—dilated cardiomyopathy	2.39e-05	0.0004	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—EGFR—dilated cardiomyopathy	2.39e-05	0.0004	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	2.37e-05	0.000398	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TNF—dilated cardiomyopathy	2.37e-05	0.000397	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—EGFR—dilated cardiomyopathy	2.36e-05	0.000396	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—EGFR—dilated cardiomyopathy	2.35e-05	0.000394	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ANKRD1—dilated cardiomyopathy	2.34e-05	0.000393	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—EGFR—dilated cardiomyopathy	2.34e-05	0.000393	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—EGFR—dilated cardiomyopathy	2.33e-05	0.000391	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	2.33e-05	0.00039	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—RAC1—dilated cardiomyopathy	2.31e-05	0.000387	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	2.29e-05	0.000385	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	2.29e-05	0.000385	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—RAF1—dilated cardiomyopathy	2.28e-05	0.000381	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—RAC1—dilated cardiomyopathy	2.26e-05	0.000379	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—EGFR—dilated cardiomyopathy	2.25e-05	0.000378	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NPPA—dilated cardiomyopathy	2.25e-05	0.000377	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	2.24e-05	0.000376	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PSEN2—dilated cardiomyopathy	2.21e-05	0.00037	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TAZ—dilated cardiomyopathy	2.2e-05	0.000369	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PSEN2—dilated cardiomyopathy	2.18e-05	0.000365	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CD36—dilated cardiomyopathy	2.16e-05	0.000363	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	2.14e-05	0.000358	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	2.13e-05	0.000358	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	2.12e-05	0.000355	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—EGFR—dilated cardiomyopathy	2.11e-05	0.000354	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD36—dilated cardiomyopathy	2.08e-05	0.000348	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	2.07e-05	0.000346	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	2.06e-05	0.000345	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	2.04e-05	0.000342	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	2.04e-05	0.000342	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	2.04e-05	0.000342	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—RAC1—dilated cardiomyopathy	2.04e-05	0.000342	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SDHA—dilated cardiomyopathy	1.99e-05	0.000334	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCL2—dilated cardiomyopathy	1.96e-05	0.000328	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AGTR2—dilated cardiomyopathy	1.96e-05	0.000328	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—RAC1—dilated cardiomyopathy	1.96e-05	0.000328	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	1.92e-05	0.000322	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.86e-05	0.000311	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.82e-05	0.000305	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.82e-05	0.000305	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	1.76e-05	0.000296	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.76e-05	0.000296	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	1.74e-05	0.000291	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	1.67e-05	0.000281	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—EGFR—dilated cardiomyopathy	1.63e-05	0.000272	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.61e-05	0.00027	CbGpPWpGaD
Dabrafenib—BRAF—Disease—RAC1—dilated cardiomyopathy	1.58e-05	0.000266	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—EGFR—dilated cardiomyopathy	1.56e-05	0.000262	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	1.54e-05	0.000259	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PSEN2—dilated cardiomyopathy	1.53e-05	0.000256	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.51e-05	0.000252	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ITGB1—dilated cardiomyopathy	1.48e-05	0.000248	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—EGFR—dilated cardiomyopathy	1.47e-05	0.000246	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.43e-05	0.00024	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GPX1—dilated cardiomyopathy	1.4e-05	0.000235	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CD36—dilated cardiomyopathy	1.37e-05	0.000229	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL2—dilated cardiomyopathy	1.36e-05	0.000227	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AGTR2—dilated cardiomyopathy	1.36e-05	0.000227	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.35e-05	0.000226	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—RAC1—dilated cardiomyopathy	1.3e-05	0.000218	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.26e-05	0.000211	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD36—dilated cardiomyopathy	1.26e-05	0.000211	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	1.26e-05	0.000211	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AGT—dilated cardiomyopathy	1.24e-05	0.000208	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AGT—dilated cardiomyopathy	1.23e-05	0.000206	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.23e-05	0.000206	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.22e-05	0.000205	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.22e-05	0.000205	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.22e-05	0.000204	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—RAC1—dilated cardiomyopathy	1.19e-05	0.000199	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.18e-05	0.000198	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	1.18e-05	0.000198	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.13e-05	0.00019	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—RAC1—dilated cardiomyopathy	1.11e-05	0.000186	CbGpPWpGaD
Dabrafenib—RAF1—Disease—RAC1—dilated cardiomyopathy	1.1e-05	0.000184	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	1.07e-05	0.000179	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.07e-05	0.000179	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AGT—dilated cardiomyopathy	1.06e-05	0.000178	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	1.06e-05	0.000177	CbGpPWpGaD
Dabrafenib—BRAF—Disease—RAF1—dilated cardiomyopathy	1.05e-05	0.000176	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—EGFR—dilated cardiomyopathy	1.05e-05	0.000176	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.04e-05	0.000175	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	1.01e-05	0.000169	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TNF—dilated cardiomyopathy	1e-05	0.000168	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ADRB2—dilated cardiomyopathy	9.89e-06	0.000166	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GPX1—dilated cardiomyopathy	9.42e-06	0.000158	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—EGFR—dilated cardiomyopathy	9.27e-06	0.000155	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CD36—dilated cardiomyopathy	9.18e-06	0.000154	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—EGFR—dilated cardiomyopathy	8.9e-06	0.000149	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GPX1—dilated cardiomyopathy	8.73e-06	0.000146	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CD36—dilated cardiomyopathy	8.5e-06	0.000142	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	8.5e-06	0.000142	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AGT—dilated cardiomyopathy	8.26e-06	0.000138	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RAC1—dilated cardiomyopathy	7.68e-06	0.000129	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AGT—dilated cardiomyopathy	7.65e-06	0.000128	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—RAF1—dilated cardiomyopathy	7.36e-06	0.000123	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AGT—dilated cardiomyopathy	7.33e-06	0.000123	CbGpPWpGaD
Dabrafenib—BRAF—Disease—EGFR—dilated cardiomyopathy	7.2e-06	0.000121	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	6.13e-06	0.000103	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EGFR—dilated cardiomyopathy	5.91e-06	9.9e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GPX1—dilated cardiomyopathy	5.41e-06	9.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EGFR—dilated cardiomyopathy	5.4e-06	9.05e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CD36—dilated cardiomyopathy	5.27e-06	8.84e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EGFR—dilated cardiomyopathy	5.05e-06	8.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EGFR—dilated cardiomyopathy	4.98e-06	8.35e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AGT—dilated cardiomyopathy	4.75e-06	7.96e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	4.72e-06	7.91e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CD36—dilated cardiomyopathy	4.59e-06	7.7e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AGT—dilated cardiomyopathy	4.14e-06	6.93e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGFR—dilated cardiomyopathy	3.49e-06	5.85e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	2.91e-06	4.87e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	2.83e-06	4.74e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	2.55e-06	4.27e-05	CbGpPWpGaD
